POTELIGEO
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
POTELIGEO by Inpharmus is mogamulizumab-kpkc is a defucosylated, humanized igg1 kappa monoclonal antibody that binds to ccr4, a g protein-coupled receptor for cc chemokines that is involved in the trafficking of lymphocytes to various organs. Approved for refractory mycosis fungoides, sézary syndrome after at least one prior systemic therapy (). First approved in 2018.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POTELIGEO (mogamulizumab-kpkc) is a monoclonal antibody that targets chemokine receptor type 4 (CCR4), a molecule expressed on certain T cells involved in lymphoproliferative disorders. It works by binding to CCR4 and depleting CCR4-expressing malignant cells through antibody-dependent cellular cytotoxicity. The drug is indicated for patients with CCR4-positive T-cell lymphomas.
$0.002BPart D
PeakProduct is in peak commercial phase with modest Part D utilization, suggesting a stable but niche market with limited team expansion opportunities.
Mechanism of Action
Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a…
Worked on POTELIGEO at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.